Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Opko Health , Inc. (NASDAQ:OPK), a pharmaceutical company with a market capitalization of $1.07 billion, disclosed in a recent SEC filing that its Compensation Committee has made significant decisions regarding executive compensation. According to InvestingPro data, the company faces some financial challenges, with revenue declining 13.78% over the last twelve months. On May 27, 2025, the Committee conducted a meeting to review compensation for the company’s executive officers and non-executive employees.
During this meeting, the Committee granted stock options to purchase common stock to named executive officers and approved bonus payments for employees, including the executives listed. The stock options have an exercise price of $1.31 per share, compared to the current trading price of $1.36, will vest annually over four years, and are set to expire ten years from the grant date. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 2.49, though it’s currently not profitable.
The executives who received stock options and bonuses include Phillip Frost, M.D., Chief Executive Officer and Chairman, who was granted 500,000 stock options and a $480,000 bonus. Jane H. Hsiao, Ph.D., Vice Chairman and Chief Technical Officer, and Elias A. Zerhouni, M.D., Vice Chairman and President, each received 500,000 stock options and a $450,000 bonus. Steven D. Rubin, Executive Vice President - Administration, was awarded 437,500 stock options and a $400,000 bonus, while Adam Logal, Senior Vice President and Chief Financial Officer, received 437,500 stock options and a $475,000 bonus.
This information is based on the 8-K filing with the SEC and reflects the company’s current compensatory arrangements for its top executives. For deeper insights into Opko Health’s financial health and detailed analysis, including 7 additional ProTips and comprehensive valuation metrics, visit InvestingPro, where you’ll find expert research reports and advanced financial analytics.
In other recent news, Opko Health Inc. reported a net loss for the first quarter of 2025, with earnings per share (EPS) missing analyst expectations. The company posted an EPS of -$0.10, compared to the forecasted -$0.09, while revenue came in at $149.9 million, falling short of the anticipated $163.14 million. Opko Health is undertaking strategic asset sales and cost reductions to improve profitability, including the sale of its oncology testing business to LabCorp. This transaction is expected to yield significant cost savings and enhance future profitability for the company. Additionally, Opko Health remains focused on developing an oral GLP-1/glucagon tablet for NASH and obesity. The company forecasts total revenues for 2025 to range between $675 million and $685 million, with anticipated costs and expenses between $825 million and $875 million. Despite the earnings miss, Opko Health’s net loss has narrowed compared to the previous year, reflecting ongoing efforts to manage costs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.